Yu Jean Liang

US Patent:

20110144184, Jun 16, 2011

Filed:

Jul 23, 2009

Appl. No.:

13/055587

Inventors:

Thomas Kristie - Silver Spring MD, US
Yu Liang - Rockville MD, US

Assignee:

The United States of America, as rep. by the Secretary, Dept of HHS - Bethesda MD

International Classification:

A61K 31/7105
A61K 31/135
A61K 31/137
A61K 31/15
A61K 31/42
A61P 31/12
A61P 31/20
A61P 31/22

US Classification:

514 44 A, 514647, 514655, 514654, 514378

Abstract:

An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.

US Patent:

20130123344, May 16, 2013

Filed:

Jan 22, 2013

Appl. No.:

13/747406

Inventors:

The United States of America, as Represented by the Secretary, Department of Health and Human Services - Bethesda MD, US
Yu Liang - Gaithersburg MD, US
Jodi Vogel - Bethesda MD, US
David J. Maloney - Point of Rocks MD, US
Anton Simeonov - Bethesda MD, US
Ajit Jadhav - Chantilly VA, US

Assignee:

The United States of America, as represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

A61K 31/551
C07D 215/14
A61K 31/506
A61K 31/5377
A61K 31/47
A61K 31/496

US Classification:

514 44 A, 514312, 51425307, 514256, 5142352, 514218, 546170, 546174, 544363, 544333, 544128, 540575

Abstract:

Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I):wherein R, R, R, R, and Rare as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.

US Patent:

20200115564, Apr 16, 2020

Filed:

Sep 19, 2019

Appl. No.:

16/576187

Inventors:

- Wilmington DE, US
YU TENG LIANG - WILMINGTON DE, US

International Classification:

C09D 5/24
C09D 7/40
C09D 7/61
C09D 127/16
C09D 11/52
C09D 11/106
C09D 11/03
C09J 9/02
C09J 11/04
C09J 127/16

Abstract:

The invention relates to a polymer thick film (PTF) conductive paste composition comprising a conductive powder, a fluoroelastomer, a silane coupling agent, and one or solvents. The PTF conductive paste composition can be used to form a printed conductor and to form an electrically conductive adhesive on various articles. The PTF conductive paste composition is provides a stretchable electrical conductor for wearables.

US Patent:

20150073039, Mar 12, 2015

Filed:

Nov 17, 2014

Appl. No.:

14/543321

Inventors:

- Bethesda MD, US
Yu Liang - Rockville MD, US
Jodi Vogel - Bethesda MD, US

International Classification:

C12N 15/113

US Classification:

514 44 A

Abstract:

An embodiment of the invention provides a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5.